在瘤学临床试验中的循环素依赖性激酶2 (CDK2) 抑制剂:一篇评论
Isabelle House1, Mari Valore-Caplan1, Elijah Maris1
1Sarah Cannon Research Institute at HealthONE, Denver, CO, USA.
Journal of immunotherapy and precision oncology
|January 15, 2025
概括
循环素依赖性激酶2 (CDK2) 抑制剂在治疗由细胞循环失调驱动的癌症方面表现有前途. 本综述涵盖了临床试验中的CDK2抑制剂,强调了它们的潜力和观察到的副作用.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 循环素依赖激酶2 (CDK2) 调节细胞周期中关键的G1-S阶段过渡.
- CDK2信号的异常与许多癌症的发病有关,包括乳腺癌,卵巢癌,前列腺癌,白血病和淋巴瘤.
- 向CDK2代表了癌症治疗的潜在治疗策略.
研究的目的:
- 审查CDK2抑制剂在临床开发中的当前情况.
- 总结这些药物的疗效和安全性概况.
- 确定最有可能从CDK2抑制中受益的患者群体.
主要方法:
- 对CDK2抑制剂的临床前和临床研究的文献搜索.
- 分析正在进行和已完成的临床试验数据.
- 对分子机制和临床结果的审查.
主要成果:
- CDK2抑制剂已经显示出有希望的临床前和早期临床活性.
- CDK2抑制剂的有效性可能在过度活跃的环林E癌症中最为明显.
- 通常观察到的副作用包括恶心,吐,腹,贫血和疲劳.
结论:
- CDK2抑制剂是一种正在发展中的向癌症疗法.
- 需要进一步的临床研究,以优化它们在特定癌症类型中的使用.
- 了解环林E过活性的作用可以指导患者选择CDK2抑制剂治疗.
更多相关视频
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.3K
11:11Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
Published on: February 21, 2019
7.3K
相关概念视频
01:45Positive Regulator Molecules
To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
02:39Positive Regulator Molecules
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:15M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:15M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...